Commentary

Video

A Physician Assistant's Perspective: Treatment Planning in NRG1+ NSCLC and Pancreatic Cancer

Author(s):

Haley M. Hill, PA-C

Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.

Related Videos
Sandip P. Patel, MD
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Neil Iyengar, MD, and Chandler Park, MD, FACP
Eunice S. Wang, MD
Marcella Ali Kaddoura, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Related Content
FDA
January 10th 2025

BBO-8520 Receives FDA Fast Track Designation in KRAS G12C–Mutated Metastatic NSCLC

Mazyar Shadman, MD, MPH, associate professor, Clinical Research Division, medical director, Cellular Immunotherapy, Fred Hutchinson Cancer Center
December 19th 2024

Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH

catalin – stock.adobe.com
January 7th 2025

Sunvozertinib Under FDA Priority Review for NSCLC With EGFR Exon 20 Insertion Mutations

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Zolbetuximab Plus Chemotherapy in Gastric/GEJ Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
January 6th 2025

Zolbetuximab Plus Chemo Wins Approval in China for CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

ES-SCLC | catalin – stock.adobe.com
January 6th 2025

Tarlatamab Earns UK Approval for Previously Treated ES-SCLC